TOKYO, June 1 (Reuters) - Japan's Shionogi & Co said on Monday the U.S. Food and Drug Administration has approved its oral ...

OSAKA, Japan, June 01, 2026--(BUSINESS WIRE)--Shionogi & Co., Ltd. (Head Office: Osaka, Japan; Chief Executive Officer: Isao Teshirogi, PhD; hereinafter "Shionogi") announced that the U.S. Food and ...

The FDA has approved the oral antiviral Xocova (ensitrelvir) for postexposure prophylaxis of COVID-19 in adults and adolescents.

Tokyo: Japan's Shionogi & Co said on Monday the U.S. Food and Drug Administration (USFDA) has approved its oral antiviral ...

Shionogi & Co. looks set to put its COVID-19 vaccine into practical use by the end of March 2022 following a government ...

In a major expansion of the pandemic treatment toolkit, the U.S. Food and Drug Administration (FDA) has officially approved ...

Japan’s Shionogi & Co. Ltd. said on Wednesday it had started a Phase II/III clinical trial for its COVID-19 vaccine candidate ...

After a prior misfire in demonstrating its protease inhibitor ensitrelvir’s potential as a COVID-19 treatment for U.S. patients, Shionogi has secured an FDA green light for the medicine in the ...

FDA approves ensitrelvir for COVID-19 post-exposure prophylaxis following phase 3 data showing efficacy against Omicron symptoms. The FDA recently approved ensitrelvir (Xocova; Shionogi), an anti–SARS ...

FDA approves Shionogi’s Xocova as First Oral Post-Exposure Covid-19 Prevention Therapy, marking a major milestone for Covid-19 prevention treatments. FDA has approved Shionogi’s Xocova (ensitrelvir) ...

Shionogi is teaming up with the Global Antibiotic Research and Development Partnership (GARDP) and the Clinton Health Access Initiative (CHAI) in a bid to boost antibiotic access worldwide. The troika ...

Find winning stocks in any market cycle. Join 7 million investors using Simply Wall St's investing ideas for FREE. Shionogi (TSE:4507) has caught investor attention after a strong past 3 months for ...